Stryker Corporation (SYK) Competitors & Peers
The 5 companies closest to Stryker Corporation on the factors that matter — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| ABT | Competitor | $108.62 | P/E 35.3RSI 69Cap 189.2 B |
| MDT | Competitor | $89.90 | P/E 24.1RSI 69Cap 115.1 B |
| BSX | Competitor | $50.46 | P/E 20.4RSI 68Cap 73.1 B |
| EW | Competitor | $93.30 | P/E 55.5RSI 67Cap 53.7 B |
| GEHC | Peer | $72.94 | P/E 16.8RSI 67Cap 33.2 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Confirmed relationships (cited)
Sourced from a public filing or disclosure — each links to its origin.
- ZBHCompetitor
Zimmer Biomet and Stryker are the two leading competitors in the large joint orthopedic reconstruction market (hip and knee implants), where Zimmer's ROSA platform competes directly with Stryker's Mako platform.
Confirmed — SEC filing / public disclosuresec.gov ↗ - ZBHCompetitor
Zimmer Biomet is Stryker's primary competitor in orthopedic implants (hip/knee arthroplasty) and competes with the Mako robotic system.
Confirmed — SEC filing / public disclosuresec.gov ↗ - JNJCompetitor
Johnson & Johnson MedTech competes with Stryker in orthopaedics (DePuy Synthes), spine, and surgical tools.
Confirmed — SEC filing / public disclosuresec.gov ↗ - SNNCompetitor
Smith & Nephew competes with Stryker in orthopedic implants, sports medicine, and advanced wound management.
Confirmed — SEC filing / public disclosuresec.gov ↗
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- IMEDPartner
Stryker completed the acquisition of Inari Medical for approximately $4.9 billion in February 2025, gaining the FlowTriever and ClotTriever peripheral vascular thrombectomy platforms.
Model-inferred, unverified — treat as a lead, not evidence - VOCERAPartner
Stryker acquired Vocera in 2022 for $3.09 billion, integrating its clinical communication and workflow platform into hospital digital infrastructure.
Model-inferred, unverified — treat as a lead, not evidence - CARE.AIPartner
Stryker acquired care.ai in 2024, integrating AI-powered ambient intelligence and computer vision into hospital workflows and surgical environments.
Model-inferred, unverified — treat as a lead, not evidence - PENCompetitor
Penumbra competes with Stryker's Neurovascular division in ischemic stroke therapy devices (aspiration catheter systems and flow diverters).
Model-inferred, unverified — treat as a lead, not evidence - PENCompetitor
Stryker's Neurovascular/Vascular division competes directly with Penumbra in ischemic stroke aspiration catheters and neurovascular thrombectomy devices.
Model-inferred, unverified — treat as a lead, not evidence - MDTCompetitor
Stryker and Medtronic compete across multiple segments including neurovascular, spine, orthopaedics, and surgical robotics.
Model-inferred, unverified — treat as a lead, not evidence - BSXCompetitor
Stryker and Boston Scientific compete in endoscopy, structural heart, and now directly in vascular intervention following SYK's Inari acquisition.
Model-inferred, unverified — treat as a lead, not evidence - ABTCompetitor
Abbott competes with Stryker in cardiac rhythm management, neurovascular, and structural heart devices.
Model-inferred, unverified — treat as a lead, not evidence - MCKSupplier
McKesson is a primary wholesale distributor of Stryker's medical devices and surgical instruments to hospitals and healthcare systems.
Model-inferred, unverified — treat as a lead, not evidence - CAHSupplier
Cardinal Health distributes Stryker's surgical supplies and devices through its medical distribution network.
Model-inferred, unverified — treat as a lead, not evidence - EWCompetitor
Stryker and Edwards Lifesciences compete in the heart valve and critical care monitoring markets.
Model-inferred, unverified — treat as a lead, not evidence